

09/121798

2. Document ID: US 20010034435 A1

L22: Entry 2 of 100

File: PGPB

Oct 25, 2001

PGPUB-DOCUMENT-NUMBER: 20010034435  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20010034435 A1

TITLE: Process and equipment for plasmid purification

PUBLICATION-DATE: October 25, 2001  
US-CL-CURRENT: 536/23.1; 435/270

APPL-NO: 09/ 774284  
DATE FILED: January 29, 2001

RELATED-US-APPL-DATA:  
RLAN

RLFD

RLPC

RLKC

RLAC

09774284

Jan 29, 2001

ABANDONED

A1

US

08887673

Jul 3, 1997

US

60022157

Jul 19, 1996

IN: Nochumson, Samuel, Durland, Ross, Yu-Speight, Audrey, Welp,  
John, Wu, Kuoewi, Hayes,  
Rexford

AB: A scalable alkaline lysis process, including procedures and  
devices for the  
isolation of large quantities (grams and kilograms) of plasmid DNA from  
recombinant E. coli  
cells. Effective, controllable, and economical operation, and consistent  
low level of host  
chromosomal DNA in the final plasmid product. Involves a series of new  
unit operations and  
devices for cell resuspension, cell lysis, and neutralization.

L22: Entry 2 of 100

File: PGPB

Oct 25, 2001

DOCUMENT-IDENTIFIER: US 20010034435 A1  
TITLE: Process and equipment for plasmid purification

BSTX:

[0008] Once the plasmid DNA is extracted from the lysed cells its  
purification has become a routine  
and important procedure for the molecular biologist. However, the scale for  
these purifications,  
often referred to as "mini-preps", is usually less than about 1 milligram of  
plasmid DNA. These  
small scale preps isolate plasmid DNA from the supernatant of lysed  
bacterial cells using a variety  
of techniques, such as ethanol precipitation. For slightly larger scale  
preparations, the primary  
techniques employed use cesium chloride centrifugation, binding and  
eluting to silica resins (in the  
presence of chaotropic salts) or binding and eluting with various anionic  
chromatography resins. In  
addition, other techniques are sometimes used in combination with the

resins mentioned, e.g., PEG  
and/or alcohol precipitation, RNase treatment, and phenol/chloroform  
extraction. There are also some  
plasmid purifications performed using analytical HPLC, in particular  
reverse phase HPLC to separate  
different plasmid forms using organic solvent systems.

59. Document ID: US 5561064 A

L22: Entry 59 of 100

File: USPT

Oct 1, 1996

US-PAT-NO: 5561064  
DOCUMENT-IDENTIFIER: US 5561064 A  
TITLE: Production of pharmaceutical-grade plasmid DNA  
DATE-ISSUED: October 1, 1996

US-CL-CURRENT: 435/320.1; 435/259, 435/91.1

APPL-NO: 8/ 192151  
DATE FILED: February 1, 1994

IN: Marquet, Magda, Horn, Nancy, Meek, Jennifer, Budahazi, Gregg

AB: The invention relates to a method for producing plasmid DNA,  
comprising the steps  
of: (a) lysing cells containing the plasmid DNA to obtain a lysate; (b)  
treating the lysate by  
a means for removing insoluble material to obtain a solute; and (c)  
applying the solute to  
differential PEG precipitations and chromatography to purify the plasmid  
DNA. In other  
embodiments of the invention, the plasmid DNA is produced with GRAS  
reagents; the plasmid DNA  
is produced in the absence of enzymes; the plasmid DNA is produced in  
the absence of organic  
extractants; the plasmid DNA is produced in the absence of mutagens; the  
lysing, treating and  
applying steps are scalable to result in the large scale manufacture of the  
plasmid DNA; and  
the lysing, treating and applying steps result in the generation of  
pharmaceutical grade  
material.

L22: Entry 59 of 100

File: USPT

Oct 1, 1996

DOCUMENT-IDENTIFIER: US 5561064 A  
TITLE: Production of pharmaceutical-grade plasmid DNA

DEPR:

This manufacturing process results in the production of milligram, gram  
and kilogram quantities of  
pharmaceutical grade plasmid DNA. In general, the method involves:  
lysing cells (e.g., bacteria,  
yeast, fungi, mammalian, insect or other cells) obtained through shake flask  
culture, bioreactor or  
fermentor propagation containing the plasmid DNA to obtain a crude  
lysate; concentrating and  
separating a partially purified DNA intermediate significantly enriched in  
plasmid DNA from host  
contaminants such as cell debris using filtration, centrifugation, any form of  
chromatography and/or  
differential precipitation methods; removing remaining contaminants such  
as proteins, RNA, lipids,  
and chromosomal DNA from the partially purified DNA intermediate by  
chromatography and/or  
differential precipitation methods; accomplishing a fine separation of  
residual contaminants and  
remaining forms of DNA by chromatography and/or differential

precipitations; removing air-borne microbes introduced during processing by sterilizing the desired plasmid fraction, and aseptically filling vials for appropriate delivery of a pharmaceutical dosage form.

DEPR:

Plasmid VCL-1005 was transformed into a standard strain of DH10B E. coli (BRL, Gaithersburg, Md.). Cells were grown in a 10 L fermentor (Braun) using standard TB medium. At the end of the exponential phase, cells were harvested by centrifugation and lysed by alkaline lysis (without the use of lysozyme). Cell debris were separated by filtration. Plasmid DNA was precipitated and fractionated by standard low pressure chromatography. Appropriate fractions were pooled and the DNA was formulated. The concentration was adjusted and the DNA was sterile filtered and filled into sterile vials. Using the process of the invention, sufficient material was produced and purified for pre-clinical and clinical studies that met the criteria of identify, purity, potency and safety of pharmaceutical products derived from E. coli as defined by the FDA.

DETL:

---

Disclosed Pharmaceutical  
Procedure Laboratory Method Manufacturing Process

---

Cell Lysis Employs

Lysozyme, No Enzymes, Alternate Tris, SDS Buffer such as Sodium Acetate, Alkaline pH and/or Tween  
.RTM. 80 instead of SDS; only GRAS reagents used Removal of Cell Centrifugation Filtration or Debris  
Centrifugation Removal of Host Uses Animal Derived High Salt Precipitation, Cell Derived Enzymes,  
Uses Organic PEG Precipitation of Contaminants: Solvents Non-Plasmid Contaminants RNA, Protein,  
Lipid, DNA Plasmid Enriched Ethanol or Similar PEG Precipitation of Crude Lysate Alcohol Plasmid DNA  
Purification of High-speed Chromatography; Column Plasmid DNA Centrifugation; is Scalable; No Toxic  
CsCl/EtBr Gradients Reagents

---

72. Document ID: US

5217593 A

L22: Entry 72 of 100

File: USPT

Jun 8, 1993

US-PAT-NO: 5217593

DOCUMENT-IDENTIFIER: US 5217593 A

TITLE: Nucleic acid purification system and method

DATE-ISSUED: June 8, 1993

US-CL-CURRENT: 204/457; 204/608

APPL-NO: 7/ 911515

DATE FILED: July 10, 1992

PARENT-CASE:

REFERENCE TO RELATED APPLICATION The present application is a continuation-in-part of co-pending application Ser. No. 07/668,856, now U.S. Pat. No. 5,139,637 filed Mar. 13, 1991 and entitled  
PLASMID PURIFICATION SYSTEM AND METHOD.

IN: MacConnell; William P.

AB: A process for the purification of DNA and the like comprises a housing having walls forming a reservoir having a chamber for containing a buffer solution, means for circulating a buffer through the reservoir, a disposable cassette within said chamber having first means including a gel for defining a first path extending between an inlet end and an outlet end, a well for introducing a bacterial sample into the path at said inlet end thereof, and a second path intersecting the first path via an elution chamber, having a collection chamber including an elution window at said outlet end, and an electrical circuit for selectively applying an electrical potential along each of the paths for selectively moving a plasmid first along the first path from the bacterial well to the elution chamber, then along the second path to the collection window at the end thereof.

L22: Entry 72 of 100

File: USPT

Jun 8, 1993

DOCUMENT-IDENTIFIER: US 5217593 A

TITLE: Nucleic acid purification system and method

BSPR:

Many techniques and apparatus exist for small scale purification of plasmid DNA. The typical prior art approach to the purification of plasmids involves a series of steps, including a collection of cells grown in liquid culture by centrifugation, separation of the bacterial chromatic (genomic) DNA, and cellular debris from the soluble contents of the bacteria by centrifugation of filtration, and concentration of the plasmid DNA apart from other cellular components by alcohol or isopropanol, absorption to solid media (i.e. ion exchange resin, glass powder, reverse phase chromatography resin, etc.), or salt precipitation. Additional purification steps may be added to these, such as phenol/chloroform extraction, secondary alcohol precipitation, protease or ribonuclease treatment to further purify the plasmid DNA.

82. Document ID: US 5075430 A

L22: Entry 82 of 100

File: USPT

Dec 24, 1991

US-PAT-NO: 5075430

DOCUMENT-IDENTIFIER: US 5075430 A

TITLE: Process for the purification of DNA on diatomaceous earth

DATE-ISSUED: December 24, 1991

US-CL-CURRENT: 536/25.41; 423/335, 435/803, 536/127, 536/25.42

APPL-NO: 7/ 629787

DATE FILED: December 18, 1990

PARENT-CASE:

This application is a continuation of application Ser. No. 07/288,515 filed Dec. 12, 1988, now abandoned.

IN: Little; Michael C.

AB: This invention is directed to a process for the purification of plasmid and other DNA, both single-stranded and double-stranded, by immobilizing the



DNA onto diatomaceous earth  
in the presence of a chaotropic agent and eluting the DNA with water or low salt buffer. The resulting purified DNA is biologically active. Also included in the invention is a process for the immobilization of DNA onto diatomaceous earth in the presence of a chaotropic agent.

L22: Entry 82 of 100

File: USPT

Dec 24, 1991

DOCUMENT-IDENTIFIER: US 5075430 A  
TITLE: Process for the purification of DNA on diatomaceous earth

BSPR:

The purification of plasmid DNA from bacterial lysates is a rate-limiting and time-consuming step in molecular biology. The preparation of plasmid DNA for cloning and other purposes generally follows the scheme established in Birnboim (1983, Methods in Enzymology 100:243-255) in which the cleared bacterial lysate is applied to a cesium chloride gradient and centrifuged for 4-24 hours. This is usually followed by the extraction and precipitation of the DNA to yield DNA that is sometimes, but not always, free of RNA, protein and chromosomal DNA. Other methods employing cleared lysates to prepare DNA of similar quality are ion exchange (Colpan et al., 1984, J. Chromatog. 296:339-353) and gel-filtration (Moreau et al., 1987, Analyt. Biochem. 166:188-193) high-performance methods. While these latter methods generally work well as alternatives for ScCl gradients, they require costly solvent delivery systems and the reprecipitation of the isolated DNA fractions since they usually contain salt or are too dilute, and are limited in the amount of DNA that can be prepared (<500 .mu.g) per run. Since typically 1 liter cultures of E. coli yield >2 mg of plasmid DNA plus much RNA and protein, the capacity of the high performance methods requires multiple cycles to process these quantities of DNA.

83. Document ID: US 5057426 A

L22: Entry 83 of 100

File: USPT

Oct 15, 1991

US-PAT-NO: 5057426  
DOCUMENT-IDENTIFIER: US 5057426 A  
TITLE: Method for separating long-chain nucleic acids  
DATE-ISSUED: October 15, 1991

US-CL-CURRENT: 435/270; 536/25.4, 536/25.41

APPL-NO: 7/ 123698  
DATE FILED: November 23, 1987

FOREIGN-APPL-PRIORITY-DATA:  
COUNTRY

	APPL-NO	APPL-DATE
DE	3639949	November 22, 1986

IN: Henco; Karsten, Stichel; Arndt, Colpan; Metin

AB: A method for the separation of long-chain nucleic acids from

other substances in solutions containing nucleic acids and other materials, comprising fixing long-chain nucleic acids in a nucleic acid-containing solution onto a porous matrix, washing the porous matrix to separate the other substances from the long-chain nucleic acids, and removing the fixed long-chain nucleic acids from the porous matrix is disclosed. A device for carrying out the method of the claimed invention is also described.

L22: Entry 83 of 100

File: USPT

Oct 15, 1991

DOCUMENT-IDENTIFIER: US 5057426 A  
TITLE: Method for separating long-chain nucleic acids

BSPR:

In the EP-A- 0 104 210 there has been described a method for separating nucleic acids up to plasmid size (<10,000 base pairs= 6 million Dalton). By using the material described therein, which is distinguished by a highly porous silica gel provided with an anion exchanger coating as employed in HPLC chromatography that is used as a carrier, for example, prepurified plasmids may be prepared in a highly pure state. Nevertheless, centrifugation steps and precipitation steps are necessary, which are not suitable for application in bulk analysis and preparation, respectively. One crucial drawback with larger molecules, for example .lambda.-phage DNA, is that during the chromatographic separation of particles <10 .mu.m the shear forces become so high that intact molecules cannot be recovered. This is all the more applicable to cellular DNA, which has a length many times that of .lambda.-phage DNA.

I. Document ID: EP 376080 A, CA 2006185 A, IT 1226210 B

L26: Entry 1 of 1

File: DWPI

Jul 4, 1990

DERWENT-ACC-NO: 1990-202539  
DERWENT-WEEK: 199027  
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Extn. and purification without centrifuging of DNA - from lambda phage(s) MJ13 phagemid(s), plasmids, and cosmid(s). by exchange treatment or lysis, and macro-filtration and ultrafiltration

PRIORITY-DATA: 1988IT-0083551 (December 22, 1988)

PATENT-FAMILY:  
PUB-NO

PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 376080 A	July 4, 1990	000	
CA 2006185 A	June 22, 1990	000	
IT 1226210 B	December 21, 1990	000	C12K

APPLICATION-DATA:  
PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

EP 376080A

December 14, 1989

1989EP-0123171

IT 1226210B

December 22, 1988

1988IT-0083551

INT-CL (IPC): C12K 401/12; C12N 15/10; C12P 19/34

IN: SCHNEIDER, C

AB: A method for the extn. and purification of DNA, starting from lambda phages, M13 phagemids, plasmids, cosmids or other like elements is claimed comprising: (a) charging the sample which undergoes an exchange treatment or lysis, followed by macrofiltration, (b) treating the macrofiltrate with a precipitant and subjecting the resulting soln. to ultrafiltration and (c) eluting and collecting the DNA fixed to the ultrafiltration support., For plasmids or cosmids lysis may be carried out with an alkaline soln. contg. a detergent, e.g. sodium deoxycholate. For lambda phages and M13 phagemids the exchange treatment may be carried out with an anionic exchange resin, e.g. DEAE and macrofiltration may be carried out with a macroporous diaphragm supported by a nitrocellulose filter. A precipitant soln. contg. a cationic detergent, e.g. cetyl-trimet hyl-ammonium bromide (CTAB) may be added to the macrofiltrate to obtain a micellar complex., ADVANTAGE - The method is used to extract and purify DNA without centrifuging steps and can be automated.

L26: Entry 1 of 1

File: DWPI

Jul 4, 1990

DERWENT-ACC-NO: 1990-202539

DERWENT-WEEK: 199027

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Extn. and purification without centrifuging of DNA - from lambda phage(s) MJ13 phagemid(s), plasmids, and cosmid(s). by exchange treatment or lysis, and macro-filtration and ultrafiltration

TTX :  
EXTRACT PURIFICATION CENTRIFUGE DNA LAMBDA PHAGE  
PLASMID COSMID EXCHANGE TREAT LYSE MACRO FILTER  
ULTRAFILTER

3. Document ID: US

6001604 A

L28: Entry 3 of 7

File: USPT

Dec 14, 1999

US-PAT-NO: 6001604

DOCUMENT-IDENTIFIER: US 6001604 A

TITLE: Refolding of proinsulins without addition of reducing agents

DATE-ISSUED: December 14, 1999

US-CL-CURRENT: 435/69.4; 435/68.1, 435/69.7, 530/344, 530/412, 530/414

APPL-NO: 8/ 967867

DATE FILED: November 12, 1997

PARENT-CASE:

This application is a continuation of U.S. Ser. No. 08/367,454, filed Dec. 29, 1994, now abandoned, which is a continuation-in-part of U.S. Ser. No. 08/175,298, filed Dec. 29, 1993 now abandoned.

IN: Hartman; Jacob R., Mendelovitz; Simona, Gorecki; Marian

AB: An improved and efficient process for the production of recombinant human insulin by folding of a proinsulin hybrid polypeptide is provided.

L28: Entry 3 of 7

File: USPT

Dec 14, 1999

DOCUMENT-IDENTIFIER: US 6001604 A

TITLE: Refolding of proinsulins without addition of reducing agents

DEPR:

Alternatively, the SOD-proinsulin hybrid polypeptide expressed by plasmid pBAST-R was purified to near homogeneity by dissolution in 8M urea, 20 mM Dithiothreitol, 50 mM NaAcetate, pH 5, and by ultrafiltration through a series of 100 kD and 50 kD membranes (Filtron). The hybrid polypeptide was concentrated on a 10 kD membrane and precipitated with (NH.sub.4).sub.2 SO.sub.4 at 40% saturation.

6. Document ID: EP

517515 A2, EP 517515 A3, JP 04360686 A

L28: Entry 6 of 7

File: DWPI

Dec 9, 1992

DERWENT-ACC-NO: 1992-408948

DERWENT-WEEK: 199250

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Purifying plasmid DNA and/or cosmid DNA from microorganism cells - by lysing cells, filtering to remove insoluble material and ultrafiltration to condense the DNA, avoiding toxic reagent usage

PRIORITY-DATA: 1991JP-0159436 (June 4, 1991)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

EP 517515 A2

December 9, 1992

E

005

C12N015/10

EP 517515 A3

June 16, 1993

000

C12N015/10

JP 04360686 A

December 14, 1992

004

C12N015/10

## APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

EP 517515A2

June 4, 1992

1992EP-0305119

EP 517515A3

June 4, 1992

1992EP-0305119

JP04360686A

June 4, 1991

1991JP-0159436

INT-CL (IPC): B01D 61/00; C12N 1/06; C12N 15/10

IN: NISHI, A, OGAWA, K

AB: Purifying plasmid DNA and/or cosmid DNA comprises (a) lysing microorganism cells contg. the plasmid DNA and/or cosmid DNA; (b) filtering the resultant lysate through a membrane filter to remove any insoluble material; and (c) subjecting the filtrate to ultrafiltration to thereby condense the DNA. The method may further comprise removing RNA originating from the cells by passing a soln. contg. an RNase and/or an aq. alkaline metal hydroxide through the ultrafilter. The cells may be lysed by treatment with an aq. alkaline hydroxide soln., such as NaOH and/or KOH, and/or a surfactant, such as sodium dodecyl sulphate (SDS)., USE/ADVANTAGE - Using the method, plasmid DNA and/or cosmid DNA can be purified to high purity from microorganism cells by simple operations without using toxic reagent

L28: Entry 6 of 7

File: DWPI

Dec 9, 1992

DERWENT-ACC-NO: 1992-408948

DERWENT-WEEK: 199250

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Purifying plasmid DNA and/or cosmid DNA from microorganism cells - by lysing cells, filtering to remove insoluble material and ultrafiltration to condense the DNA, avoiding toxic reagent usage

TT X:

PURIFICATION PLASMID DNA COSMID DNA MICROORGANISM  
CELL LYSE CELL FILTER REMOVE INSOLUBLE MATERIAL  
ULTRAFILTER CONDENSATION DNA AVOID TOXIC REAGENT